diabetic macular edema

Partner Perspective: Patient Case Study - CONTINUOUS MICRODOSING™ TREATMENT WITH ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg
Improving visual function, retinal integrity in DME patient
Improving visual function, retinal integrity in DME patientDiagnosing and treating diabetic macular edema (DME) can pose a challenge for ODs. A. Paul Chous, OD, MA, FAAO, CDE, examines a case of non-center involved DME and the challenges he faced when treating one patient.
Using imaging to manage diabetic retinopathy
Using imaging to manage diabetic retinopathyCreating a partnership between the optometrists and retinal practices will enhance the care of patients and serve as a continuing source of education and reference for the OD community. This constant communication will help diabetic patients who are suffering from this multifactorial disease that affects their bodies. DR must be addressed from the optometrist’s point of view, retinal specialist’s point of view, and the primary-care physician’s point of view.
Novel DME treatment derives from multimodal activityALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.